Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reissue Patent
2007-06-26
2007-06-26
Wax, Robert A. (Department: 1653)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S007600, C514S021800, C514S023000, C514S251000, C514S276000, C424S049000, C424S054000, C424S535000, C424S655000, C530S365000, C530S833000
Reissue Patent
active
09994164
ABSTRACT:
Glutathione (GSH) is a tripeptide of extreme importance as a catalyst, reductan, and reactant. It can be depleted intra-cellularly either by forming a direct complex with an electrophilic agent (accomplished investigationally by agents such as bromobenzene or diethyl maleate), by way of inhibition of synthesis, or by subjecting cells to oxidant stress. Most cells, except for epithelia cells, do not have a direct transport capacity for intact GSH. Non-epithelial cells must either transport precursor substrates for GSH synthesis or salvage amino acids from circulating GSH for reuse in intracellular resynthesis. Dietary cysteine is a rate limiting substrate for the synthesis of glutathione and also inhibits GSH efflux. Although GSH is synthesized from precursors in virtually all cells, the liver is the main source of plasma GSH. Protection and support of liver function is paramount to elevating GSH levels. The disclosure is also of a unique combination of nutritional supplements including n-acetyl cysteine, vitamin C, 1-glucosamine, n-acetyl d-glucosamine, quercitin, sylimarin, Alpha lipoic acid and high protein, low fat whey that are combined to support various bodily systems involved in glutathione synthesis, reutilization and storage; all intended to elevate glutathione concentration in the mammalian cell.
REFERENCES:
patent: 4256760 (1981-03-01), Los
patent: 4277496 (1981-07-01), Los
patent: 4292403 (1981-09-01), Duermeyer
patent: 5290571 (1994-03-01), Bounous et al.
patent: 5456924 (1995-10-01), Bounous et al.
patent: 5696109 (1997-12-01), Malfroy-Camine et al.
“Screening of Potential Chemropreventive Agents Using Biochemical Markets of Carcinogenesis” by Sheela Sharma, Jill D. Stutzman, Gary J. Kelloff and Vernon E. Steele, Cancer Research 54, 5848-5855, Nov. 15, 1994.
Low Blood Glutathione Levels in Healthy Aging Adults, pp. 720-725, Calvin A. Long, et al.
a-Lipoic Acid: Biological Effects and Clinical Implications, pp. 177-183, Trent W. Nichols, Jr. M.D.
Glutathione: Systemic Protectant Against Oxidative and Free Radical Damage, pp. 155-171, 173-176, Parris M. Kidd, Ph.D.
Importance and Regulation of Hepatic Glutathione, pp. 251-266, Laurie D. Deleve, M.D., Ph.D. et al.
Probiotics in Human Medicine, pp. 439-442, R. Fuller.
Aids Wasting Syndrome as an Entero-Metabolic Disorder: The Gut Hypothesis, pp. 40-45, 47-53, Mitchell Kaminski, Jr., M.D., et al.
The Effects of L-Glutamine, N-Acetyl-D-Glucosamine, Gamma-Linolenic Acid and Gamma-Oryzanol on Intestinal Permeability.
PROMT on STN, Information Access Company, 1998: 1310, BioDynamax Supplement—Ultra Antioxidants Tablets, Product Alert (Dec. 22, 1997) ISSN: 0740-3801.
Keller Robert H.
Kirchenbaum David
Frommer & Lawrence & Haug LLP
Santucci Ronald R.
Vit-Immune, L.C.
Wax Robert A.
LandOfFree
Method of treating glutathione deficient mammals does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method of treating glutathione deficient mammals, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of treating glutathione deficient mammals will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3858917